Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rani Therapeutics Holdings (RANI)
NASDAQ:RANI
RESEARCH TOOLSreports
Holding RANI?
Track your performance easily
RANI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.82 - $8.75
Previous Close$2.28
Volume70.39K
Average Volume (3M)54.19K
Market Cap
$121.77M
Enterprise Value$128.83M
Total Cash (Recent Filing)$30.90M
Total Debt (Recent Filing)$35.25M
Price to Earnings (P/E)―
Beta-0.31
Next Earnings
Nov 07, 2024EPS Estimate
-$0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.18
Shares Outstanding53,406,508
10 Day Avg. Volume56,157
30 Day Avg. Volume54,187
Standard Deviation0.31
R-Squared0.00076
Alpha0.00595
Financial Highlights & Ratios
Price to Book (P/B)48.00
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-3.47
Forecast
1Y Price Target
$12.33Price Target Upside413.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Rani Therapeutics Holdings News
PremiumCompany Announcements
Rani Therapeutics Reevaluates Equity Financing StrategyBulls Say, Bears Say
Bulls Say
Market OpportunityRaniPill may be uniquely positioned for the $30B+ GLP-1/obesity space, where size of the patient population makes efficient delivery important for margins and supply chains.
Technology PotentialRani has a potentially transformative technology platform that can turn essentially any drug in the $260B biologics market into an oral, without impacting bioavailability.
ValuationRani is viewed as highly undervalued compared to similar historical drug delivery precedents.
Bears Say
Financial PerformanceFinancial results reported a net loss of $0.51 per share, indicating ongoing financial challenges.
Market UptakeSlower than projected market uptake for key products could impact revenue growth and profitability.
Regulatory RisksFailure to achieve regulatory approvals for key pipeline projects, notably RT-102 and RT-105, presents significant risk.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
The estimated number of people who visited one or more of the websites owned by Rani Therapeutics Holdings
Desktop Users
Mobile Users
RANI FAQ
What was Rani Therapeutics Holdings’s price range in the past 12 months?
Rani Therapeutics Holdings lowest stock price was $1.82 and its highest was $8.75 in the past 12 months.
What is Rani Therapeutics Holdings’s market cap?
Currently, no data Available
When is Rani Therapeutics Holdings’s upcoming earnings report date?
Rani Therapeutics Holdings’s upcoming earnings report date is Nov 07, 2024 which is in 50 days.
How were Rani Therapeutics Holdings’s earnings last quarter?
Rani Therapeutics Holdings released its earnings results on Aug 06, 2024. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.335 by $0.075.
Is Rani Therapeutics Holdings overvalued?
According to Wall Street analysts Rani Therapeutics Holdings’s price is currently Undervalued.
Does Rani Therapeutics Holdings pay dividends?
Rani Therapeutics Holdings does not currently pay dividends.
What is Rani Therapeutics Holdings’s EPS estimate?
Rani Therapeutics Holdings’s EPS estimate is -$0.29.
How many shares outstanding does Rani Therapeutics Holdings have?
Rani Therapeutics Holdings has 29,290,064 shares outstanding.
What happened to Rani Therapeutics Holdings’s price movement after its last earnings report?
Rani Therapeutics Holdings reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.335. Following the earnings report the stock price went down -2.8%.
Which hedge fund is a major shareholder of Rani Therapeutics Holdings?
Currently, no hedge funds are holding shares in RANI
---
Rani Therapeutics Holdings Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.33 (413.75% Upside)
$12.33 (413.75% Upside)
Blogger Sentiment
Bullish
RANI Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 0.2%
Last 30 Days ▲ 0.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.78%
12-Months-Change
Fundamentals
Return on Equity
-227.14%
Trailing 12-Months
Asset Growth
-47.64%
Trailing 12-Months
Company Description
Rani Therapeutics Holdings
Rani Therapeutics Holdings Inc is a clinical stage biotherapeutics company advancing technologies to enable the development of orally administered biologics. It has developed the RaniPill capsule, proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing.
---
RANI Earnings Call
Q4 2024
0:00 / 0:00
---
RANI Stock 12 Month Forecast
Average Price Target
$12.33
▲(413.75% Upside)
Technical Analysis
Best Analysts Covering RANI
1 Year
1 Year Success Rate
2/7 ratings generated profit
1 Year Average Return
-22.71%
reiterated a buy rating 3 months ago
Copying Julian Harrison's trades and holding each position for 1 Year would result in 28.57% of your transactions generating a profit, with an average return of -22.71% per trade.
---